4.6 Review

Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis

Related references

Note: Only part of the references are listed.
Article Pathology

Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC

Malene Nielsen et al.

Summary: This study evaluated the histological response of PM-PC patients to PIPAC treatment, showing a high frequency of KRAS mutation in patients. NGS can be used to detect predictive mutations in PM-PC.

JOURNAL OF CLINICAL PATHOLOGY (2021)

Article Oncology

A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis

Naminatsu Takahara et al.

Summary: This study investigated the maximum tolerated dose and recommended dose of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel in pancreatic cancer patients with peritoneal metastasis. The results showed the feasibility and potential effectiveness of this treatment regimen as a first-line therapy for pancreatic cancer patients with peritoneal metastasis.

INVESTIGATIONAL NEW DRUGS (2021)

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Review Oncology

The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review

Alexandre Brind'Amour et al.

Summary: In this study, the safety and efficacy of intraperitoneal chemotherapy for PDAC-derived PM were investigated, with different therapeutic strategies including CRS and HIPEC. Results suggest that intraperitoneal chemotherapy may be safe for short-term disease control in highly selected patients with PDAC-derived PM, but long-term survival remains poor.

CLINICAL & EXPERIMENTAL METASTASIS (2021)

Review Oncology

Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review

Andreas Larentzakis et al.

Summary: This systematic review looked into the potential role of HIPEC in the treatment of pancreatic adenocarcinoma. Further studies are needed to validate the use of HIPEC as an adjuvant therapy in resectable pancreatic adenocarcinoma.

ONCOLOGY LETTERS (2021)

Review Oncology

Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions

Paul H. Sugarbaker et al.

Summary: The Whipple procedure for pancreas cancer can lead to long-term survival in 20% of patients, with gemcitabine being used for regional chemotherapy and administered via hyperthermic intraperitoneal chemotherapy (HIPEC) and long-term normothermic intraperitoneal chemotherapy (NIPEC). The use of intraperitoneal gemcitabine is supported by pharmacologic data and may improve local-regional control, leading to successful multimodality strategies.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Article Oncology

Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection

Antonios-Apostolos K. Tentes

Summary: HIPEC following R-0 resection is a feasible and safe adjuvant treatment for pancreatic cancer, which may significantly decrease local-regional failures and result in increased overall survival. Further studies combining intraperitoneal and systemic perioperative chemotherapy may provide additional benefits for patients undergoing pancreatic cancer resection.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Article Oncology

Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41

David Padilla-Valverde et al.

Summary: HIPEC combined with gemcitabine after cytoreductive surgery may improve the survival of patients with pancreatic cancer by reducing neoplastic volume and residual pancreatic cancer stem cells.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Article Oncology

Pancreatic Adenocarcinoma, Version 2.2021

Margaret A. Tempero et al.

Summary: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with a major challenge being advanced disease at diagnosis. While survival rates have not significantly changed, newer treatments, including targeted therapies, offer hope for patients. The manuscript focuses on systemic therapy approaches for locally advanced and metastatic disease.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Article Mathematical & Computational Biology

Meta-analysis of the difference of medians

Sean McGrath et al.

BIOMETRICAL JOURNAL (2020)

Review Biotechnology & Applied Microbiology

Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress

Amelia Barcellini et al.

ONCOTARGETS AND THERAPY (2020)

Review Oncology

Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer

Oliver S. Eng et al.

JOURNAL OF SURGICAL ONCOLOGY (2019)

Article Medicine, General & Internal

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

W. J. van Driel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Review Oncology

Peritoneal Metastases from Gastrointestinal Cancer

Paul H. Sugarbaker

CURRENT ONCOLOGY REPORTS (2018)

Review Gastroenterology & Hepatology

Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes

Andrew McGuigan et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

Article Oncology

Strategies to improve local control of resected pancreas adenocarcinoma

Paul H. Sugarbaker

SURGICAL ONCOLOGY-OXFORD (2017)

Review Oncology

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Sanket S. Mehta et al.

INDIAN JOURNAL OF SURGICAL ONCOLOGY (2016)

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Gastroenterology & Hepatology

Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer

Mathias Worni et al.

PANCREAS (2013)

Review Gastroenterology & Hepatology

Peritoneal carcinomatosis

Federico Coccolini et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2013)

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Review Oncology

Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer

Anil Kamath et al.

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Article Medicine, General & Internal

Meta-analysis of observational studies in epidemiology - A proposal for reporting

DF Stroup et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)